Program
VRC07-523LS
Also written as “TMB-380”, “VRC07523LS” and “TMB-365/TMB-380”.
Its studies are led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TaiMed Biologics | 21 open or running | phase 2since Mar 2, 2022 | Mar 2, 2022 | May 2027phase 2 · NCT07215468 |
| Gilead Sciences | 10 open or running | phase 2since Mar 7, 2022 | Mar 7, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2022First study: phase 2 study in HIV-1-infectionNew to TaiMed BiologicsTaiMed Biologics · NCT05275998 · 51 enrolled · United States
- Mar 7, 2022Gilead Sciences's first study: phase 2 study in HIV-1-infectionNew to Gilead SciencesGilead Sciences · NCT05281510 · 20 enrolled · South Africa
- Oct 9, 2025Phase 2 study in HIV -1 InfectionTaiMed Biologics · NCT07215468 · 88 enrolled · United States
Ahead
- May 2027Primary completion: phase 2 study in HIV -1 InfectionTaiMed Biologics · NCT07215468
TargetBeta
“VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope.”study text, by rule · the study
Other programs on CD4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| TMB-365rule | TaiMed Biologics | phase 2 | 3 |
| Allogeneic BAFF-L-expressing CAR T Cells LMY-922rule | Luminary Therapeutics | phase 1 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07215468HIV -1 Infection · United States | 2 | Active, not recruiting | TaiMed Biologics | May 2027 | 88 |
| NCT05281510HIV-1-infection · South Africa | 2 | Completed | Gilead Sciences | Jan 16, 2025 | 20 |
| NCT05275998HIV-1-infection · United States | 2 | Completed | TaiMed Biologics | Nov 20, 2024 | 51 |
How it is read
Names in the registry
- “TMB-380”, 1 entry
- “VRC07523LS”, 1 entry
- “TMB-365/TMB-380”, 1 entry
Codes read as this program: TMB380.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.